Functional roles of SRC signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities.
Oncogene
; 42(22): 1786-1801, 2023 06.
Article
de En
| MEDLINE
| ID: mdl-37120696
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease with a 5-year survival rate of <10%. Aberrant activation or elevated expression of the tyrosine kinase c-SRC (SRC) is frequently observed in PDAC and is associated with a poor prognosis. Preclinical studies have revealed a multifaceted role for SRC activation in PDAC, including promoting chronic inflammation, tumor cell proliferation and survival, cancer cell stemness, desmoplasia, hypoxia, angiogenesis, invasion, metastasis, and drug resistance. Strategies to inhibit SRC signaling include suppressing its catalytic activity, inhibiting protein stability, or by interfering with signaling components of the SRC signaling pathway including suppressing protein interactions of SRC. In this review, we discuss the molecular and immunological mechanisms by which aberrant SRC activity promotes PDAC tumorigenesis. We also provide a comprehensive update of SRC inhibitors in the clinic, and discuss the clinical challenges associated with targeting SRC in pancreatic cancer.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du pancréas
/
Carcinome du canal pancréatique
Limites:
Humans
Langue:
En
Journal:
Oncogene
Sujet du journal:
BIOLOGIA MOLECULAR
/
NEOPLASIAS
Année:
2023
Type de document:
Article
Pays d'affiliation:
Australie